Ahmed Salous, DO
Family Medicine · Oklahoma City, OKNPI 1245766864
Payments from drug & device makers
Across 429 payments — averaging $19.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$990
- Pfizer$816
- Lilly USA, LLC$777
- AbbVie$749
- Amgen$480
- plus $4K from 28 others
What the payments were for
- Food & beverage$8,45499%
- Education$951%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $1,106 |
| GSK | 63 | $990 |
| Pfizer | 55 | $816 |
| Lilly USA, LLC | 50 | $777 |
| AbbVie | 42 | $749 |
| Amgen | 14 | $480 |
| Astellas Pharma US Inc | 17 | $457 |
| Boehringer Ingelheim | 21 | $387 |
| Novo Nordisk | 21 | $313 |
| Sanofi-aventis U.S. LLC | 6 | $300 |
| Sumitomo Pharma America, Inc. | 16 | $298 |
| Dexcom, Inc. | 10 | $274 |
| Abbott | 9 | $251 |
| Exact Sciences | 8 | $226 |
| Phathom Pharmaceuticals, Inc. | 7 | $211 |
| Bayer | 10 | $177 |
| Merck | 10 | $158 |
| Axsome Therapeutics, Inc. | 2 | $131 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Mylan Specialty L.p. | 3 | $72 |
| Kowa Pharmaceuticals America, Inc. | 3 | $49 |
| Viatris Specialty LLC | 1 | $30 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Genentech USA, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Edwards Lifesciences | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $12 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$239
- BREZTRI$231
- Repatha$124
- FreeStyle Libre$123
- The Cologuard Plus Collection Kit$117
- AREXVY$117
- TZIELD$117
- DEXCOM G7 GSS (161)$117
- VOQUEZNA$116
- Symbravo$116
- AIMOVIG$115
- SOLIQUA 100/33$114
- FARXIGA$114
How this compares
$8,549 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $155,200 |
| JardianceEmpagliflozin | 120 | $151,012 |
| MounjaroTirzepatide | 97 | $149,331 |
| RybelsusSemaglutide | 72 | $123,754 |
| FarxigaDapagliflozin Propanediol | 89 | $92,819 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $89,409 |
| EliquisApixaban | 78 | $88,861 |
| JanuviaSitagliptin Phosphate | 41 | $60,675 |
| TrulicityDulaglutide | 46 | $52,114 |
| MyrbetriqMirabegron | 36 | $39,939 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $36,395 |
| LinzessLinaclotide | 29 | $29,030 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $22,312 |
| XareltoRivaroxaban | 11 | $19,412 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $16,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $313 | $278,954191 claims |
| Lilly USA, LLCMounjaro, Trulicity | $777 | $201,444143 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $387 | $167,826148 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $990 | $125,803181 claims |
| PfizerEliquis, Nurtec Odt | $816 | $103,12290 claims |
| AstraZenecaFarxiga, Symbicort | $1,106 | $96,241102 claims |
| MerckJanuvia | $158 | $60,67541 claims |
| Astellas Pharma US IncMyrbetriq | $457 | $39,93936 claims |
| AbbVieLinzess | $749 | $29,03029 claims |
| Johnson & JohnsonXarelto | $13 | $19,41211 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $298 | $10,48419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Charles LunnOklahoma City$1.4M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.